Adjuvant Statin Therapy for Esophageal Adenocarcinoma: a cost-effectiveness analysis by Fong Soe Khioe, Rebekah et al.
1 
 
Title: Adjuvant Statin Therapy for Esophageal Adenocarcinoma: a cost-utility 
analysis 
Authors: Rebekah Fong Soe Khioe, M.S.1, Chris Skedgel, Ph.D.1, Andrew Hart1, 2, 
Mike Lewis2, Leo Alexandre1, 2 
Authors’ affiliations and addresses: 1 Norwich Medical School, Bob Champion 
Research and Education Building, James Watson Road, University of East Anglia, 
Norwich Research Park, NR4 7UQ, UK. 
2Department of Gastroenterology, Norfolk & Norwich University Hospital, Colney 
Lane, Norwich, NR4 7UY, UK. 
Authors’ Email:  
Rebekah Fong Soe Khioe, MSc: R.Fong-Soe-Khioe@uea.ac.uk 
Chris Skedgel, PhD: C.Skedgel@uea.ac.uk 
Andrew Hart, FRCP, MD: A.Hart@uea.ac.uk 
Mike Lewis FRCS, MD: michael.lewis@nnuh.nhs.uk 
Leo Alexandre, MRCP: Leo.Alexandre@uea.ac.uk 
Corresponding Author:  
Rebekah Fong Soe Khioe 
R.Fong-Soe-Khioe@uea.ac.uk, 01603 593942 
Acknowledgements: The authors did not receive any grant support.  
Author contributions: R.FSK, C.S, L.A, A.H and M.L contributed to the writing and 
revisions of the final manuscript. C.S. designed model with R.FSK contributing to the 
collection and analysis of data.   
Conflicts of Interest: R.FSK, C.S, L.A, A.H and M.L have no conflicts of interest to 
declare. 
2 
 
ABSTRACT 
Background  
Emerging preclinical evidence indicates statins, medications commonly used in the 
prevention of cardiovascular disease, inhibit proliferation, promote apoptosis and 
limit invasiveness of esophageal adenocarcinoma (EAC). Population-based 
observational data demonstrates statin treatment after diagnosis of EAC is 
associated with significant reductions in all-cause and cancer-specific mortality. A 
feasibility study of adjuvant statin therapy following potentially curative resection for 
EAC has completed, with planned progression to a full phase III randomised 
controlled trial 
Aim 
To estimate the cost-utility of statin therapy following surgical resection for EAC from 
an NHS perspective.  
Methods 
A Markov model was developed to estimate the costs and outcomes (quality 
adjusted life years, QALYs) for hypothetical cohorts of patients with EAC exposed or 
not exposed to statins following potentially curative surgical resection. Model 
parameters were based on estimates from published observational and trial data. 
Costs, utilities and transition probabilities were modelled to reflect clinical practice 
from a payer’s perspective. Probabilistic and one-way sensitivity analyses were 
performed to account for uncertainty in key parameters.  
Results 
Overall, a cost-saving of £6,781 per patient was realised with statin treatment 
compared to no statins. In probabilistic sensitivity analysis, 99% of all iterations were 
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cost-saving and  99% of all iterations were less than £20,000 per QALY gained. 
These results were robust to changes in the price and effectiveness of statins..  
Conclusions 
The cohort exposed to statins had lower costs and better QALY outcomes than the 
no statin cohort. Assuming a causal relationship between statin exposure and 
outcomes suggests that statins following resection of EAC is a cost-saving 
treatment.  
Key Words: HMG-CoA; cost-effectiveness; esophageal cancer.  
Key Points for Decision Makers: 
- Epidemiological and trial data can be efficiently applied and drawn together 
within modelling studies to estimate the associated economic impact of 
treatments upon UK NHS resources (i.e. the cost per quality-adjusted life-year 
(QALY)). 
- Assuming a causal improvement in survival post-resection of esophageal 
adenocarcinoma (EAC), statin therapy is very likely to be a cost-effective 
treatment strategy 
- The development of randomised controlled trials to establish the efficacy of 
statins as an adjuvant treatment for EAC are warranted from a clinical 
perspective. 
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1. INTRODUCTION 
 
Esophageal cancer (EC) is the 8th most common cancer worldwide and is associated 
with a dismal prognosis[1]. In the United Kingdom (UK) there were 8,784 newly 
registered cases in 2013 and 7,701 deaths, ranking EC as the 4th and 6th cause of 
cancer death in men and women respectively in 2014[2]. Within the western world 
esophageal adenocarcinoma (EAC) is the commonest histological subtype of 
esophageal malignancy[3]. Since the 1970s the incidence of EAC has risen six-fold 
in England and Scotland, with the UK currently having the highest age-standardised 
incidence rate in the western world[4], [5]. In 2012-13 the cost of esophageal cancer 
was estimated at £134 million, approximately 0.3% of total NHS costs and as the 
incidence continues to rise, the economic burden to National Health Service (NHS) 
resources will increase[6].  
The mainstay of treatment in patients with potentially curable EAC is surgery with or 
without chemotherapy or chemo-radiotherapy[1]. Most recent trial data show that 
patients with esophageal and junctional adenocarcinomas treated with pre-operative 
chemo-radiotherapy have a five-year survival of 45%, at best[7], with most deaths 
attributable to recurrent disease. 
There is currently a substantial research focus on the anti-cancer effects of statins 
(3-hydroxy-3-methylglutaryl coenzyme A [HMG-CoA] reductase inhibitors), 
medications commonly prescribed for the prevention of primary and secondary 
cardiovascular disease[8]. There is growing experimental evidence to suggest statins 
promote apoptosis, inhibit proliferation and limit invasiveness in EAC cell lines[9]–
[12]. There is strong epidemiological evidence for statins reducing the risk of cancer-
related mortality. The most recent systematic review and meta-analysis of 
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observational studies included 95 cohorts with over 1.1 million cancer patients (from 
multiple sites) demonstrated post-diagnosis statin use was associated with a 
significant reduction in all-cause mortality (HR 0.65, 95% CI 0.60 – 0.72), with similar 
effect sizes for both cancer-specific mortality and disease-free survival[13]. A 
population-based cohort study of 4445 patients with esophageal cancer conducted in 
the UK with linkage between the Clinical Practice Research Datalink (CPRD), (a 
large primary care database of anonymised medical records of over 11.3 million 
patients from over 560 UK general practices), National Cancer Data Repository, and 
Office for National Statistics Datasets similarly demonstrated significant reductions in 
EC-specific mortality (HR 0.63 95% CI 0.38 - 0.96) and all-cause mortality (HR 0.63 
95% CI 0.43 - 0.92) associated with statin use following diagnosis of EAC[14]. Statin 
use was modelled as a time-dependent exposure, adjusted for age, gender, body 
mass index, smoking status, cardiovascular disease, diabetes mellitus, surgery, 
chemotherapy, radiotherapy and medication use (aspirin, angiotensin-converting 
enzyme inhibitors, and angiotensin 2-receptor blockers, beta-blockers and 
nonsteroidal anti-inflammatory drugs). Based on the emerging experimental and 
observational data, the STAT-ROC feasibility study[15] has been completed to 
determine the prospect of investigating adjuvant statin therapy in the setting of 
prevention of recurrence of potentially curative EAC. The feasibility study was a 
multi-centre, double-blind, parallel group, randomised trial to estimate the 
recruitment, retention, drug adherence, and safety of statins, which strongly supports 
the feasibility of a future phase III randomised-controlled trial, which is currently in 
development.  
In deciding patient care to the individual, delivery of service is influenced by the 
impact of care upon the individual’s survival and quality of life. Additionally, the cost 
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burden to the NHS is likely to affect the choice of treatment recommended by 
decision-makers. The National Institute for Health and Care Excellence (NICE) 
clinical guideline CG181 recommend[8] patients are treated with statins, for primary 
and secondary prevention of cardiovascular disease at the NICE threshold value of 
£20,000 cost per QALY gained, but the ‘value for money’ of statins as an adjuvant 
treatment for EAC recurrence following potentially curative surgery is unknown.  
In light of the economic burden upon NHS resources and emerging experimental and 
observational data surrounding statin treatment for patients post-diagnosis of EAC, 
we evaluated the cost-effectiveness of statin therapy following potentially curative 
resection (esophagectomy) for locally advanced EAC. Current UK practice, as 
reflected in a recent national audit is either surgery alone or in combination with peri-
operative chemotherapy [used in > 80%][16]. We modelled, integrating observational 
and trial data, the potential for statin therapy to be cost-effective in terms of a cost 
per quality-adjusted life year (QALY) gained. The aim of this study was to determine 
the cost-effectiveness of statin therapy as an adjuvant treatment for EAC.  
2. METHODS 
 
A probabilistic state-transition model was developed in Microsoft Excel 2013 
(Microsoft Corporation, Redmond, WA, United States of America) to estimate the 
cumulative cost and QALY outcomes associated with exposure to statin use 
alongside standard care (surgery +/- perioperative chemotherapy) versus no statin 
use with standard care only, in patients following surgical resection post-diagnosis of 
EAC. A UK NHS payer perspective was adopted, and following NICE methods 
guide, costs and outcomes were discounted at 3.5% [17].  
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2.1. Model Structure  
The state-transition model consisted of three possible health states by which patients 
progressed through. All patients began in the disease-free survival (DFS) state, 
following curative resection for EAC, and could transition to EAC recurrence and 
subsequently death by EAC or due to other causes (background mortality). Patients 
were also able to transition from DFS to death due to other causes, without 
transitioning to EAC recurrence. At entry into the model, patients in the statin arm 
were assumed statin users once daily and were at risk of statin-specific adverse 
events (AEs) within each health state. Patients in the non-statin arm received 
standard care only.  
The model had a one-year cycle length and a lifetime horizon (30 years, reflecting 
life expectancy in this population).  A half-cycle correction was applied to the first 
cycle. Figure 1 presents the model structure.   
 
2.2. Transition probabilities and key model assumptions 
The baseline population was modelled to reflect the demographic characteristics of 
patients identified in the CPRD with a diagnosis of incident esophageal or 
esophagogastric junction cancers. The cohort from the CPRD were 71 years old and 
69% were male, which was assumed as the baseline population within the model.  
To model the clinical efficacy, the baseline patient population were modelled to 
reflect data from the Medical Research Council Adjuvant Gastric Infusional 
Chemotherapy (MAGIC) randomised controlled trial (RCT). Briefly, the trial recruited 
503 patients, predominately from the UK and Netherlands, to compare peri-operative 
chemotherapy to no chemotherapy in patients with resectable gastro-oesophageal 
adenocarcinoma. This trial was selected since the active arm largely reflects current 
UK practice: most patients (>80%) treated with curative intent for EAC in the UK 
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receive peri-operative chemotherapy. A parametric function was fitted to the disease-
free survival (DFS) curve observed in the peri-operative chemotherapy arm to inform 
the baseline DFS in the model[18]. A Weibull distribution had the best fit to the 
observed data by the Kolmogorov-Smirnov statistic and Aikake’s Information 
Criterion[19]–[21] and is illustrated in Figure 2. All patients were assumed eligible for 
statin therapy when they entered the model at baseline. The effect size for the 
association between post-diagnostic statin use and all-cause mortality from UK 
observation data (HR 0.63, 95% CI: 0.43;0.92) was assumed to approximate the 
effect size of statin use on DFS in the model[14]. Median adherence to statin therapy 
in the intended patient population from feasibility data is 91.5%[15]. To be 
conservative, in a sensitivity analysis we assumed adherence to statins was 
90%.The DFS benefit of statins was assumed to persist for as long as patients 
continued on treatment until recurrence or death. Reflecting clinical outcomes 
observed in the MAGIC trial[18], patients in both arms of the model were assumed to 
be at risk of EAC recurrence for 6 years following successful resection with no 
recurrences beyond 6 years. Patients who were non-statin users or withdrew from 
statin therapy due to an adverse event had the same risk of progression as patients 
in the no treatment arm. i.e. baseline DFS.  
 
The risk of adverse events as a result of statin use were modelled based on current 
clinical practice and literature[22], [23]. Where an adverse event attributed to statins 
occurred patients were assumed to discontinue the drug. Finegold et al.[23] report 
patients allocated to statin treatment versus placebo, ashaving a statistically 
significantly higher risk of transaminitis (elevated transaminases alanine 
transaminase (ALT) and/or aspartate transaminase (AST) to greater than three times 
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the upper limit normal (ULN)[22]) and type 2 Diabetes Mellitus (T2DM). The 
increased relative risk of transaminitis and of T2DM, due to statins were reported as 
31.5% and 24.7%, given an average follow-up of 3.19 years[23]. The rate of new 
incident cases were adjusted for the follow-up period reported and were assumed to 
persist over the lifetime patients remained in the model. Patients experiencing 
transaminitis were assumed to discontinue statins and reverted to the baseline risks 
of disease progression, whilst patients developing diabetes continued treatment. 
Allocation to statins are associated with large relative but low absolute risk of 
rhabdomyolysis (a severe form of myopathy characterised by muscle breakdown 
with myoglobin released into the systemic circulation)[22], [24]. Whilst statin-
associated rhabdomyolysis events are rare, clinically, they are important as they 
would be expected to lead to discontinuation of treatment and in severe cases, acute 
renal failure and death[25]–[27]. Given these potentially severe consequences, the 
risk of rhabdomyolysis was included in the model to take a conservative approach in 
considering the costs and outcomes of statin treatment. Furthermore, to assume a 
simplistic model approach, the effectiveness of statins in the primary and secondary 
prevention of cardiovascular disease[24], [28], [29] were not included in the model, to 
focus wholly on the benefits in the context of esophageal cancer. Patients were also 
subject to an age-sex specific risk of all-cause mortality (ACM) derived from UK 
national life tables[30]. Assuming a predicted mortality of 8.51 per 100,000[31], ACM 
was adjusted for potential double counting of EAC mortality. The parameter values 
used within the model are shown in Table 1.  
 
2.3. Costs  
The costs of statin use against no treatment were modelled with reference to the 
effect size demonstrated in Alexandre et al’s[14] population-based data from the 
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perspective of the UK NHS healthcare system. All costs were inflated to 2016 prices 
using the Personal Social Services Research Unit (PSSRU) UK[32] hospital and 
community health services index. Where available, unit costs were drawn from the 
British National Formulary 71[33], NHS reference costs 2014/15[34] and NICE 
Technology Assessment (TA) costing reports[35].   
The annual cost of statin treatment was calculated based on the price of a 28-day 
supply of each of the five statins (Simvastatin, Pravastatin, Atorvastatin, 
Rosuvastatin and Fluvastatin) weighted by the proportions of patients using each 
formulation and multiplied to an annual cost (£2.62 x 365/28 = £34.15/year)[33]. In a 
sensitivity analysis we tested using the single highest monthly price in place of the 
weighted average price (Rosuvastatin; £29.60/month, £387.03/year).   
It was assumed that patients in a disease-free state following surgery would have 
follow-up clinic appointments with an upper gastrointestinal (GI) surgeon every 6 
months in the first two years and then yearly in the following three to five years. The 
cost of an EAC recurrence was estimated from NHS Reference Costs 2014/15 
[34](HRG code in brackets) and included one multidisciplinary team meeting 
(CMDT_C), appropriate investigations; CT scan (RD20A), endoscopy (FZ57Z) and 
X-ray (DAPF) and any recommended oncology treatment or best supportive care. 
Oncology treatment costs following a recurrence were estimated assuming 25% of 
patients received treatment with chemotherapy, 30% radiotherapy, 1% 
chemoradiotherapy, and 10% stent[36]. The remaining 34% were assumed to 
receive treatment only with best supportive care. Median survival following 
recurrence was assumed to be 4 months, based upon the clinical experience of an 
upper GI surgeon (M.L), and was assumed to be the same in the both groups. Costs 
at death were based on estimates from a Marie Curie, national primary care audit of 
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end of life care. Hospital inpatient and community care, were estimated as £425 and 
£145 per day, and patients were assumed to have a median survival of 120 days (17 
days as inpatient hospital care and 103 days as community care)[37].  
The annual cost of type 2 diabetes mellitus was drawn from a study by Hex et al.[38]. 
This study was identified in a systematic review that sought to estimate the health 
economic cost of T2DM treatment estimates[39]. The cost of liver transaminitis and 
rhabdomyolysis were drawn accordingly from NHS reference costs 2014/15[34]. The 
cost of rhabdomyolysis was calculated as a weighted average cost of resource use 
related to the severity of a rhabdomyolysis event (life threatening, hospitalisation, 
death or disability) and the percentage of patients experiencing each during a 
rhabdomyolysis event.  
2.4. Utilities  
Utility estimates for the model health states and adverse events were identified 
where possible, from a literature search of systematic reviews, relating to the patient 
event. Utility estimates assessed from the European Quality of Life-5 Dimension-3 
Level (EQ-5D-3L) questionnaire, derived from UK time trade-off values, was 
preferred. 
The baseline utility estimate for patients in the disease-free survival state was based 
upon baseline EQ-5D-EL data of 41 patients undergoing esophagostomy or total 
gastrectomy, entering a RCT feasibility study. Mean utility was estimated using UK 
time trade-off values, and was assumed from the study in the model as 0.80[40].  
The utility of EAC recurrence was estimated by Boer et al.[41], using standard 
gamble techniques, from a cohort of 50 patients, interviewed, following 
esophagetomy for EAC with an average age of 63 years.  
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Estimates of the utility of abnormal liver function tests were calculated by Donnan et 
al.[42] from a cohort of 99 UK patients, answering the EQ-5D-3L questionnaire. The 
utility of type 2 diabetes mellitus (T2DM) was identified from a systematic review 
conducted reporting T2DM utilities for economic models[43]. The measure of utility 
from the systematic review  were estimates obtained from the United Kingdom 
Diabetes Study (UKPDS) to measure the utilities of type 2 diabetic patients[44]. As 
no utility estimate of rhabdomyolysis was found, in line with the assumptions drawn 
by Mitchell et al.[45], it was assumed the utility value would be comparable to severe 
myopathy[46]. The disutility was assumed from Mitchell et al.[45] and is presented in 
table 2, along with a summary of all utilities included in the model. 
2.5. Analyses performed 
The cost-effectiveness result was calculated in terms of expected costs and QALYs.  
If there was a dominant alternative associated with lower costs and equivalent or 
better QALY outcomes, this alternative would be highlighted, and no incremental 
cost-effectiveness ratio (ICER) would be presented. Only if one alternative was 
associated with better QALY outcomes and increased costs, the expected cost per 
QALY gained was calculated. i.e. the ICER.  
Uncertainty was incorporated into the model through one-way sensitivity analysis, on 
the cost of statins, follow-up, EAC recurrence and on the expected DFS rate, with 
incremental cost and QALYs only being measured. An alternative scenario analysis 
on the risk, cost and utility of rhabdomyolysis was estimated, as well as a scenario 
allowing for 25% non-adherence. Probabilistic sensitivity analysis (PSA) was 
performed by replacing base-case estimates for key parameters with probability 
distributions and sampling values from these distributions over 5000 iterations. The 
PSA was conducted with a normal distribution around the hazard ratio of statin 
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therapy. Beta distributions were assumed around the probabilities of an adverse 
event occurring, and the associated utility values. A gamma distribution with a shape 
parameter of 1 was conducted on the costs associated with statin treatment and the 
costs associated with EAC recurrence and death. Uncertainty was reported in terms 
of 95% confidence intervals around key outcomes and graphically with a cost-
effectiveness acceptability curve (CEAC).  We also report the probabilities that a 
statin strategy was dominated (greater costs, worse QALY outcomes), cost-saving 
(lower costs, equivalent or better QALY outcomes) or cost-effective relative to the 
NICE £20,000 threshold. Additionally, we report the expected value of perfect 
information (EVPI) [47]. Finally, we estimate the net budget impact of statins for each 
1,000 patients treated.   
 
3. RESULTS 
 
3.1. Base-Case Results 
In the base-case analysis, statins appeared to be the dominant therapy, and 
therefore a cost-saving treatment of £6,781 (95% CI: £12,471; £1,375) (See Table 
3). Including the costs of treatment, statin patients led to greater costs per patient of 
£487 due to adverse events occurring and follow-up appointments. However, statins 
led to a decrease of £7,268 in EAC recurrence costs. Lifetime expected QALYs per 
patient was 4.93 with statins and 3.25 without statins, representing a gain of 1.68 
(95% CI: 0.12; 4.41) QALYs per patient prescribed statins. The budget impact 
analysis suggested net savings of £6.40 million (95% CI: £12.47m; - £1.38m) for 
each 1,000 EAC patients receiving statin therapy. With respect to recurrences and 
adverse events, statins were associated with a decrease of 269 EAC recurrences 
and 20 additional cases of transaminitis, 34 cases of diabetes mellitus per 1,000 
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patients and 0.43 cases of rhabdomyolysis, including 0.04 deaths, per 10,000 
patients. The expected value of perfect information was estimated as £3.07 per 
patient. 
3.2. Sensitivity Analysis 
Consistent with the base-case results, the probabilistic sensitivity analysis suggested 
a 98.94% probability that statins were cost-effective relative to a £20,000 per QALY 
gained threshold, a 98.86% probability of being cost-saving, and only a 0.36% 
probability that the statin alternative was dominated (more costly and less effective). 
These probabilistic results are illustrated in the scatter plot in Figure 3.  
One-way sensitivity analysis showed that substituting the highest cost statin was still 
associated with cost savings and QALY gains with statins (-£4,545; 1.68 QALYs), 
and threshold analysis showed that a statin strategy would meet a £20,000 per 
QALY gained threshold at an annual statin cost of up to £6,406 (£534 per month) or 
a hazard ratio as high as 0.99.  Decreasing the modelled expected disease-free 
survival curve of the benefit of statins (Fig.2), by 50%, from 34% to 17%, improved 
cost savings and QALY gains (-£8,659; 2.18 QALYs) whilst increasing it by 50%, 
from 34% to 51%, reduced savings and QALY gains (-£2,151; 0.35 QALYs) but 
statins remained a dominant strategy under both scenarios. Where the cost of 
palliative care was halved, the cost saving result also decreased (-£3,651; 1.68). 
Finally, a scenario analysis of doubling the cost of follow-up and halving the cost of 
EAC recurrence showed statins remained cost saving and led to QALY gains (-
£6,136; 1.68). An alternative scenario analyses of doubling the incidence, mortality 
and the cost of rhabdomyolysis and halved its utility did not change the dominance of 
statins (-£6,778; 1.68 QALYs). Allowing for non-adherence by assuming 25% of 
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patients did not take the drugs they received did not change the overall results. The 
results from the one-way sensitivity analyses are presented in Table 4.  
4. DISCUSSION 
Following esophagectomy and current peri-operative treatment modalities, there are 
no trial data to support longer-term adjuvant therapies to reduce the risk of 
recurrence and improve the prognosis in patients with EAC. Based on the recent 
pharmacoepidemiological data demonstrating large reductions in esophageal 
cancer-specific and all-cause mortality with statin use post-diagnosis of EAC[14], we 
modelled the cost-effectiveness of statin therapy alongside standard treatment in 
preventing recurrence and/or death. The results suggest that statin use in patients’ 
following resection of EAC improve outcomes and if proven to be effective in a future 
trial, represents very favourable value for money. Indeed, the model suggests that 
statin therapy could save the NHS £6,781 per patient, or £6.40 million for every 
1,000 patients with EAC. Whilst monetary cost savings to the NHS have clearly been 
highlighted, the reduction in the number of EAC recurrences could have further 
implications on resource use and capacity within secondary care. Increases in 
productivity through a reduction in chemotherapy and radiotherapy treatments are 
potential resource impacts that providers within the NHS could consider.   
We performed a number of validation checks consistent with the Assessment of the 
Validation Status of Health Economic (AdViSHE) decision models checklist[48]. The 
face validity of the conceptual model and input data were confirmed by experienced 
gastroenterologists. Extreme values were tested against expected outcomes and 
check sums were used to trace the initial cohort through the model logic. The model 
structure was validated against a similar model of statins in the chemoprevention in 
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Barrett’s Esophagus [49]. Finally, the face validity of the final estimates, including 
costs and survival, were assessed by clinical experts. 
To our knowledge, this is the only study presenting the results of the cost-
effectiveness of statins alongside standard treatment following esophagectomy with 
curative intent for EAC. Given the 98.86% probability of the cost-saving result and 
98.94% probability of statins being cost-effective in probabilistic sensitivity analysis, 
assuming causality, we believe the results we present are robust. This is supported 
by the sensitivity analyses that consistently showed that statins represented strong 
value for money across a range of assumptions and parameter values. In absence of 
definitive evidence around the cost of follow-up and cost of recurrence, even when 
both were adjusted to double the parameter values, statins continued to remain cost-
saving. Additionally, the sensitivity analyses conducted also suggests that statins 
leads to gains in QALYs.   
There are a number of limitations in the analysis. Firstly, we are aware the model did 
not include the related CVD benefits due to statin exposure. As statins reduce 
mortality, the health care related costs accrued due to additional life years, should be 
modelled. Arguably, other conditions associated with advanced age, such as 
dementia and hip fracture are leading causes of mortality, and may account for 
possible future medical costs, that should also be modelled. As the aim of the cost-
effectiveness is to inform the efficacy of statin therapy in patients with EAC, and to 
limit the scope to the condition of interest, we simplified the model to exclude the 
related CVD benefits.  
A second limitation is the assumption of the primary measure of benefit being 
informed from epidemiological population-data[14]. While the roles of reverse 
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causation bias and unmeasured confounding cannot be excluded, such 
observational research is the highest level of available evidence (there are no 
current trial data) on which to base this economic analysis. Even if the assumed 
effect size of statin therapy (HR=0.63) is an overestimate, adjuvant statin therapy 
remains cost-effective assuming much lower estimates of effect size with statin 
treatment (i.e. HR = 0.99). In modelling the EAC-mortality and all-cause mortality 
rates from observational data, we assumed the effect size of statins was applicable 
to patients following surgery for EAC and reflects the effect of statins on disease free 
survival. While the low EVPI of £3.07 suggests that there would be little value in 
refining the estimates of effect size from observational data alone; to change clinical 
practice and include the adjuvant treatment of EAC as a new licenced indication for 
statins would require a phase III RCT, hence superseding the value of EVPI alone. 
The safety profile of statins is well described and favourable. However, factors other 
than EVPI, such as the clinical evidence of the disease area are reported to have 
potential weight on recommendations for further research, and should be carefully 
considered[50].  
5. CONCLUSIONS 
Statin therapy for patients following potentially curative resection of EAC appears to 
reduce NHS cost, assuming there is a casual reduction in the risk of cancer 
recurrence and of death. 
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TABLES 
 Table 1: Key-input parameter estimates. 
Input Parameters 
Rate* 
(SD) 
Active 
statin** 
(SD) 
PSA 
Distribution 
Rate source 
Mortality   
 
 
Baseline EAC 
mortality 42.20%  
 Alexandre et al, 2016; T3[14] 
HR(EAC 
mortality)|statin 0.61  
Normal (95%CI: 
0.38 – 0.96) 
Alexandre et al, 2016; T3[14] 
Baseline all-cause 
mortality 66.50%  
 Alexandre et al, 2016; T3[14] 
HR(all-cause 
mortality)|statin 0.63   
Normal (95%CI: 
0.43 – 0.92) 
Alexandre et al, 2016; T3[14]   
   
 
 
Adverse events   (α,β)  
Liver tranasminases 
>3ULN 0.3757% 0.4945% 
 
Beta, 
(7.191,594.809) Finegold, 2014; T2[23] 
Diabetes mellitus 0.6892% 0.8609% 
 
Beta, 
(13.142,588.858)  Finegold, 2014; T2[23] 
Rhabdomyolysis 0.0000% 0.0054% 
 
Beta, 
(0.0787,601.921) Law, 2006; T3[51] 
EAC = Esophageal adenocarcinoma; HR = Hazard Ratio; ULN = Upper limit normal 
(Liver transaminases occurs when the transaminases alanine transaminase (ALT) is 
greater than 3 times the ULN; T2 = Table 2 (Data drawn from table 2 in the source 
article); T3 = Table 3 (Data drawn from table 3 in the source article). 
*The Rate describes the baseline risk parameters of patients inputted into the model, 
without statin therapy. 
**The Active Statin describes the risk parameters of patients inputted into the model, 
reflecting stating therapy.   
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Table 2: Unit costs, utilities and sources. 
Unit costs and 
utilities 
Annual 
Cost (£) 
PSA 
distribution 
(k, θ) 
Source 
Costs    
Statins £34.15 Gamma, 
 (34.15,1) 
BNF 2015[33] 
Follow-up, years 1-2 £334.00 Gamma, 
 (334.00,1) 
NHS Reference Costs 2014/15 (HRG:WF01A)[34] 
Follow-up, years 3-5 £167.00 Gamma, 
 (167.00,1) 
NHS Reference Costs 2014/15 (HRG:WF01A)[34] 
EAC recurrence £3,685.62 Gamma, 
 (3,685.62,1) 
NHS Reference Costs 2014/15,  
TA191[34], [35] 
  
Palliative Care  
       
£24,181.0
0  
Gamma, 
 (24,181.00,1) 
Liver Transaminases 
>3ULN 
£1,686.00 Gamma, 
 (1,686.00,1) 
NHS Reference Costs, 2014/15 (HRG:GC17K)[34] 
Diabetes Mellitus £513.54 Gamma, 
 (513.54,1) 
Hex et al, 2012[38] 
Rhabdomyolysis £5,300.62 Gamma, 
 (5,300.62,1) 
NHS Reference Costs, 2014/15 (HRG:AA35F)[34] 
    
  Utility PSA 
distribution 
(α,β) 
Source 
Utilities    
Disease-free following 
EAC 
0.80 Beta,  
(554.99,47.02) 
Bowrey et al, 2015[40]  
Esophageal cancer 
recurrence 
0.41 Beta,  
(246.82, 
355.18) 
Boer et al, 2002[41] 
Liver transaminases 
>3ULN 
0.79 Beta,  
(475.58, 
126.42) 
Donnan et al, 2009[42] 
Diabetes mellitus 0.79 Beta,  
(472.57, 
129.43) 
Clarke et al, 2002[44] 
Rhabdomyolysis 0.14 Beta, 
(84.28, 
517.72) 
Mitchell et al, 2015[45] 
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EAC = Esophageal adenocarcinoma; HR = Hazard ratio; ULN = Upper limit normal 
(Liver transaminases occurs when the transaminases alanine transaminase (ALT) is 
greater than 3 times the ULN. 
Table 3: Base case results: expected cost and QALYs per patient 
 
Statin 
Therapy  
No Statin 
Therapy  Difference 
Total Costs (per patient) £12,265 £19,046 
-£6,781  
(95% CI: £12,471; £1,375) 
    Follow-Up costs £814 £674 £140 
    Statin-drug costs £216 - £216 
    Statin-related AE 
costs £258 £127 £131 
    EAC recurrence costs £10,977 £18,245 -£7,268 
    
QALYs 4.93 3.25 
1.68  
(95% CI: 0.12; 4.41) 
 
ICER (£/QALY) Cost Saving Dominated 
 
AE = Adverse events; EAC = Esophageal adenocarcinoma; QALYs = Quality 
adjusted life years; ICER = Incremental cost effectiveness ratio. 
 
 
Table 4: Deterministic Sensitivity Analyses results 
 Cost QALY 
Highest Price of Statins = £387 -£4,545 1.68 
Cost of follow up increases by 50% and EAC recurrence 
reduced by 50% -£6,136 1.68 
HR|(EAC mortality) Statins = 0.99 -£32 0.04 
Cost of palliative care reduced by 50% -£3,651 1.68 
Double the cost of rhabdomyolysis, the baseline risk and 
disutility -£6,778 0.84 
DFS rate decreases by 50% (34% to 17%) -£8,659 2.18 
DFS rate increases by 50% (34% to 68%) -£2,151 0.35 
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FIGURES 
Fig.1 
Figure 1 presents the probabilistic state-transition model as a schematic of the 
possible health states patients’ progress through within each one-year cycle over a 
lifetime horizon. All patients begin in the disease-free survival health state, and can 
either remain in that state, have an EAC recurrence, or death due to background 
mortality or due to EAC. Once a patient progress’ to EAC recurrence, the patient will 
continue to remain in that state or die due to EAC or due to other mortalities.  
  
 
 
 
 
 
 
Disease-free 
survival
EAC Death
Background 
Mortality
EAC recurrence
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Fig.2  
Modelled Kaplan-Meier Estimates of Disease-free Survival and fitted curves. 
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Fig.3. 
Incremental cost-effectiveness plane of Statin use versus no statin use. Each point 
represents the incremental cost-effectiveness ratio (ICER), drawn from each of the 
5000 iterations in probabilistic sensitivity analysis.  
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